Перейти к основному содержанию
rd

Знания

HIPRA R&D Projects

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19

HIPRA laboratory R&D

Preclinical evaluation of PHH-1V candidate against SARS-CoV-2 in non-human primates

HIPRA R&D Projects

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

HIPRA R&D Projects

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

HIPRA R&D Projects

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

laboratory vaccines

Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months

human health laboratory

Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial

Preclinical evaluation of a COVID19 vaccine

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

About RBDCOV Talks

RBDCOV Talks HIPRA’s participation: In 5 minutes, what is a recombinant protein vaccine?